

29 May 2023

ASX Announcement

## Update on Nasodine AAT Appeal Timetable

---

**Firebrick Pharma Limited** (ASX:FRE) (**Firebrick**) announces today that the AAT conciliation meeting<sup>1</sup>, which was previously scheduled for 30 May, has been deferred and a new date is yet to be agreed between the Parties (Firebrick, TGA<sup>2</sup> and AAT). The deferral was requested by the AAT due to the unavailability of the nominated AAT Member on 30 May. In the meantime, Firebrick submitted its Statement of Issues Facts and Contentions (**SIFC**) on 2 March, but only received the TGA's SIFC on 25 May which was originally scheduled for 12 May. This delay in delivery of the TGA's SIFC would have allowed the Company only four days to file a response and fully prepare for the conciliation. Under the circumstances, Firebrick supports the deferral of the conciliation. Once a new date is agreed, Firebrick will advise the market.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded with the mission to commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also has a third patent family covering the Nasodine formulation, which has been granted in Australia. Firebrick is currently completing a second Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results will also be important for securing regulatory approvals and partnerships in major markets outside Australia.

**Media enquiries:**

Heidi Cuthbert  
+61 411 272 366  
heidi.cuthbert@multiplier.com.au

**Investor enquiries:**

Investors@firebrickpharma.com

---

<sup>1</sup> The conciliation is part of Firebrick's appeal to the Administrative Appeals Tribunal (**AAT**) against the TGA's decision not to approve Nasodine® Nasal Spray ("Nasodine") based on existing clinical data.

<sup>2</sup> Technically, the party to the proceeding is the Minister for Health and Aged Care